Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm

Publication date: Available online 23 April 2019Source: Diabetes & Metabolic Syndrome: Clinical Research & ReviewsAuthor(s): Azza Khalifa Bin Hussain, Elamin Abdelgadir, Fauzia Rashid, Abeer Al Haj, Puja Thadani, Alaaeldin M.K. BashierAbstractFor more than a century, the high occurrences of coronary and peripheral artery diseases in diabetes mellitus patients has been well recognised; despite that, the ability to improve CV event rates by optimizing glycaemic control has remained elusive. Nevertheless, the last decade has seen several cardiovascular outcome clinical trials (CVOTs) of many antihyperglycemic agents that reported promising results for cardiovascular and renal outcomes. This leads to a hot debate on the ideal drug choice for first-line treatment in T2DM. The purpose of this paper is to review the evidence supporting the use of metformin, sodium-glucose cotransporter 2 (SGLT2) inhibitors and incretin-based therapies for the management of individuals with T2DM and, discuss the rationale for selection.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research